- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03246529
A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous TransplantatIon in Subjects With MM (GENESIS)
A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma - The GENESIS Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Part 1: This lead-in period, designed to ascertain the dose of BL-8040, enrolled a total of 12 subjects to an open labeled treatment to assess the efficacy, safety, PK and PD parameters of treatment with G-CSF 10 µg/kg/day and BL-8040 1.25 mg/kg, per study protocol to goal collection of ≥ 6 × 10^6 CD34+ cells/kg.
- Part 2: Following the successful completion of Part 1, a total of 122 subjects were randomized into Part 2 of the study which employed a double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Koln
-
Köln, Koln, Germany, 50923
- University of Koln
-
-
-
-
-
Budapest, Hungary, 1097
- Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases
-
Debrecen, Hungary, 4032
- University of Debrecen
-
-
-
-
-
Catania, Italy, 95124
- Div. Clinicizzata di Ematologia - Policlinico Vittorio Emanuele
-
Reggio Calabria, Italy, 89133
- Presidio Ospedaliero Morelli Viale Europa
-
-
-
-
-
Barcelona, Spain, 08041
- Hospital de la Santa Creu i Sant Pau
-
Madrid, Spain, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 135250
- Hospital University Ramon y Cajal
-
-
-
-
California
-
Los Angeles, California, United States, 167817
- UCLA Medical Center
-
-
Florida
-
Gainesville, Florida, United States, 100278
- University of Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Loyola University Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland
-
-
Minnesota
-
Rochester, Minnesota, United States, 55902
- Mayo Clinic
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- The Washington University School of Medicine
-
-
Ohio
-
Cincinnati, Ohio, United States, 45221
- University of Cincinnati
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute in University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed Multiple Myeloma prior to enrolment and randomization.
- At least 1 week (7 days) from last induction cycle of combination/multi-agent cyto-reductive chemotherapy (e.g., KRD [carfilzomib, lenalidomide, dexamethasone] or VRD (e.g., bortezomib, lenalidomide, dexamethasone) or last single agent chemotherapy (e.g., lenalidomide, pomalidomide, bortezomib, dexamethasone, etc.) prior to the first dose of G-CSF for mobilization.
- Eligible for autologous hematopoietic stem cell transplantation according to the Investigator's discretion.
- The subjects should be in first or second CR (including CR and SCR) or PR (including PR and VGPR).
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Adequate organ function at screening as defined as below:
Hematology:
- White blood cell counts more than 2.5 x 109/L
- Absolute neutrophil count more than 1.5 x 109/L
Platelet count more than 100 x109/L Renal Function:
• GFR value of ≥15 mL/min/1.732 calculated by MDRD equation
Hepatic function:
- ALT and/or AST ≤ 2.5 x ULN
- Total Bilirubin ≤ 2.0 x ULN unless the subject has Gilbert disease
Coagulation test:
- INR or PT: ≤1.5xULN unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants
- aPTT: ≤1.5xULN unless subject is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants
- Male subjects must agree to use an adequate method of contraception starting with the first day of G-CSF administration through 30 days after the last dose of study drug.
- Patients must have a signed study informed consent prior to entering the study.
Exclusion Criteria:
- Previous history of autologous or allogeneic-HCT.
- Failed previous HSC collections or collection attempts.
Taken any of the listed below concomitant medications, growth factors or stimulating agents within the designated washout period:
- Dexamethasone: 7 days;
- Thalidomide: 7 days;
- Lenalidomide: 7 days;
- Pamolidomide: 7 days;
- Bortezomib: 7 days;
- Carfilzomib: 7 days;
- G-CSF: 14 days;
- GM-CSF or Neulasta®: 21 days;
- Erythropoietin or erythrocyte stimulating agents: 30 days;
- Eltrombopag, romiplostim or platelet stimulating agents: 30 days;
- Carmustine (BCNU): 42 days/6 weeks;
- Daratumumab: 28 days;
- Ixazomib: 7 days.
- Received >6 cycles lifetime exposure to thalidomide or lenalidomide.
- Received >8 cycles of alkylating agent combinations.
- Received >6 cycles of melphalan.
- Received prior treatment with radioimmunotherapy (e.g., radionuclides, holmium).
- Received prior treatment wiht venetoclax.
- Plans to receive maintenance treatment within 60 days post-engraftment (e.g., lenalidomide, bortezomib, pomalidomide, thalidomide, carfilzomib, etc.)
- Has received a live vaccine within 30 days of the planned start of G-CSF administration. Seasonal flu vaccines that do not contain live virus are permitted.
- Known active CNS metastases or carcinomatous meningitis.
- A history of allergic reactions attributed to compounds of similar chemical or biologic composition to BL-8040, G-CSF, or other agents used in the study.
- Has an active infection requiring systemic therapy or uncontrolled infection.
- Has a known additional malignancy that is progressing or requires active treatment.
- Has an underlying medical condition that would preclude study participation.
- Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- O2 saturation < 92% (on room air).
- Personal history or family history of Long QT Syndrome or Torsade de Pointes.
- History of unexplained syncope, syncope from an uncorrected cardiac etiology, or family history of sudden cardiac death.
- Myocardial infarction, CABG, coronary or cerebral artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for congestive heart failure within 3 months or greater than Angina Pectoris Class >2 or NYHA Heart Failure >2.
- ECG in screening showing QTcF > 470 msec, and/or PR > 280 msec,.
- Mobitz II 2nd degree AV Block, 2:1 AV Block, High Grade AV Block, or Complete Heart Block, unless the patient has an implanted pacemaker or implantable cardiac defibrillator (ICD) with backup pacing capabilities.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is notin the best interest of the subject to participate, in the opinion of the treating investigator.
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the screening visit through 30 days after the last dose of study drug.
- Has a known history of HIV (HIV 1/2 antibodies)
- Has known active Hepatitis B (e.g., Hepatitis B Surface Antigen [HBsAg] reactive) or Hepatitis C (e.g., Hepatitis C Virus [HCV] RNA [qualitative] is detected).
- Untreated or unsuccessfully treated Hepatitis B or C.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BL-8040 1.25 mg/kg + G-CSF
Double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
|
Up to 2 SC injections of BL-8040 are anticipated during the study.
Injections of G-CSF per standard of care
|
Active Comparator: Placebo + G-CSF
Double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
|
Up to 2 SC injections of Placebo are anticipated during the study.
Injections of G-CSF per standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg With up to 2 Apheresis Sessions
Time Frame: From first day of study treatment (G-CSF) until day of second apheresis which was planned to occur on Day 6
|
Percentage of subjects mobilizing ≥6 × 10^6 CD34+ cells/kg with up to 2 apheresis sessions in preparation for autologous hematopoetic cell transplantation (auto-HCT) after treatment with G-CSF + single administration of BL-8040/placebo. Based on central laboratory data. |
From first day of study treatment (G-CSF) until day of second apheresis which was planned to occur on Day 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects Mobilizing ≥2 × 10^6 CD34+ Cells/kg in 1 Apheresis Session
Time Frame: From first day of study treatment (G-CSF) until day of first apheresis which was planned to occur on Day 5
|
Percentage of subjects mobilizing ≥2 × 10^6 CD34+ cells/kg in 1 apheresis session after treatment with G-CSF + single administration of BL-8040/ placebo.
|
From first day of study treatment (G-CSF) until day of first apheresis which was planned to occur on Day 5
|
Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg in 1 Apheresis Session
Time Frame: From first day of study treatment (G-CSF) until day of first apheresis which was planned to occur on Day 5
|
Percentage of subjects mobilizing ≥6 × 10^6 CD34+ cells/kg in 1 apheresis session after treatment with G-CSF + single administration of BL-8040/ placebo.
|
From first day of study treatment (G-CSF) until day of first apheresis which was planned to occur on Day 5
|
Time to Neutrophil Engraftment, After Auto-HCT
Time Frame: End of engraftment period, which was defined as 29 days post transplantation
|
Time to neutrophil engraftment after auto-HCT, where engraftment was defined as absolute neutrophil count (ANC) ≥0.5 × 10^9/L for 3 days or ≥1.0 × 10^9/L for 1 day following the conditioning regimen associated nadir.
|
End of engraftment period, which was defined as 29 days post transplantation
|
Time to Platelet Engraftment, After Auto-HCT
Time Frame: End of engraftment period, which was defined as 29 days post transplantation
|
Time to platelet engraftment, after auto-HCT, where engraftment was defined as the first of 3 consecutive measurements of platelet count ≥20 × 10^9/L without platelet transfusion support for 7 days following the conditioning regimen associated nadir.
|
End of engraftment period, which was defined as 29 days post transplantation
|
Subjects With Graft Durability at 100 Days Post Transplant/ Early Termination
Time Frame: Day 100 Post-Transplantation (± 7 days)
|
Subjects achieving graft durability were defined as meeting the following 2 criteria:
This analysis was performed in part 2 of the study only. |
Day 100 Post-Transplantation (± 7 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John DiPersio, MD, Washington University School of Medicine
- Principal Investigator: Crees Zachary, MD, Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Immunologic Factors
- Adjuvants, Immunologic
- Lenograstim
Other Study ID Numbers
- BL-8040.SCM.301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Placebo +G-CSF
-
Institute of Liver and Biliary Sciences, IndiaCompletedSevere Alcoholic HepatitisIndia
-
Zhongnan HospitalNot yet recruitingGranulocyte Colony-Stimulating FactorChina
-
Hanyang University Seoul HospitalMinistry of Health & Welfare, KoreaCompletedCerebral Palsy | Neurodegeneration | G-CSF | Peripheral Blood Mononuclear Cells
-
Hanmi Pharmaceutical Company LimitedCompletedHealthyUnited States
-
Institute of Liver and Biliary Sciences, IndiaCompletedChronic Liver DiseaseIndia
-
Sun Yat-sen UniversityRecruitingPD-1 Inhibitor | G-CSFChina
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedDiamond Blackfan AnemiaUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedAplastic AnemiaUnited States
-
Axaron Bioscience AGCompleted
-
MenoGeniX, Inc.National Institutes of Health (NIH); National Institute on Aging (NIA)CompletedPostmenopausal SymptomsUnited States